Securities Investigation: Levi & Korsinsky Investigates Disc Medicine, Inc. (IRON) on Behalf of Investors

Core Viewpoint - Disc Medicine, Inc. is under investigation for potential violations of federal securities laws following the FDA's issuance of a Complete Response Letter (CRL) for its lead therapeutic candidate, bitopertin, which delays approval and impacts revenue projections [1][2][5]. Group 1: FDA Response and Impact - On February 13, 2026, the FDA issued a CRL for bitopertin, indicating that the application cannot be approved in its current form and requires additional data submissions [2]. - Bitopertin was positioned as a transformative therapy for approximately 4,000 Erythropoietic protoporphyria (EPP) patients, but the CRL delays potential approval until at least 2027, affecting near-term revenue expectations [3]. - Following the CRL announcement, Disc shares fell by 21.9%, reflecting market expectations for a favorable FDA outcome based on prior communications from the company [4]. Group 2: Investigation Focus - The investigation by Levi & Korsinsky is centered on whether Disc and its senior executives made misleading statements regarding the regulatory prospects of the bitopertin program, not fully disclosing the risks faced in interactions with the FDA prior to the CRL [5].